Agenus Inc.

31 clinical trials · Sponsor

Record	Firm	Date
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma (NCT05529316)	Agenus Inc.	2022-12-12
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer (NCT05608044)	Agenus Inc.	2022-11-30
Study of AGEN1571 in Participants With Advanced Solid Tumors (NCT05377528)	Agenus Inc.	2022-07-19
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors (NCT05025085)	Agenus Inc.	2021-10-04
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer (NCT05033132)	Agenus Inc.	2021-10-01
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma (NCT04607200)	Agenus Inc.	2021-02-01
A Study in Subjects With Advanced Solid Tumors (NCT04156100)	Agenus Inc.	2019-12-10
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer (NCT04121676)	Agenus Inc.	2019-09-26
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer (NCT03894215)	Agenus Inc.	2019-06-01
Phase 1a Study to Evaluate Immunogenicity of ASV® (NCT03673020)	Agenus Inc.	2019-05-16
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer (NCT03860272)	Agenus Inc.	2019-03-20
A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) (NCT03495882)	Agenus Inc.	2017-12-18
Study of AGEN1884 With Pembrolizumab in 1L NSCLC (NCT03411473)	Agenus Inc.	2017-10-04

Track Agenus Inc. automatically

Every clearance here is in the API, with alerts when new ones post.